NEW YORK (GenomeWeb News) – Beckman Coulter Life Sciences announced late Thursday it has acquired flow cytometry firm Blue Ocean Biomedical for an undisclosed amount.
According to Beckman Coulter, the deal provides it with low complexity analyzers that integrate automated sample preparation. It added the acquisition will allow it to directly address emerging flow cytometry market trends.
Blue Ocean's instruments are based on a "sample in, result out," or SIRO, approach that Beckman said represents "a fundamental change in the routine clinical analysis sector." Its SIRO solution is the only one for clinical flow cytometry.
"This acquisition provides both immediate opportunity and long-term value," Scott Atkin, president of Beckman Coulter Life Sciences, said in a statement. "The simplification of customer workflows will be dramatic. We'll be able to offer customers an extended line of market leading technology while expanding our reach within a key segment for flow cytometry."
Blue Ocean is based in Pembroke Pines, Fla.
Beckman Coulter Life Sciences is part of Beckman Coulter, which was acquired last year by Danaher for $6.8 billion.